A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Clinical trial NCT04191499 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04191499
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-29
- Primary completion
- 2023-09-29
- Enrollment
- 325
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.